Clinical trials: Leukemia, Acute Myelogenous (AML)
Acute Myeloid Leukemia
Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)
This study will test daily dosing of atovaquone at established pneumocystis jiroveci pneumonia (PJP) prophylaxis dosing in combination with standard induction chemotherapy for de novo AML.
- Trial name
- ATACC AML (NCT03568994)
- Testing
- Atovaquone, Cytarabine, Daunorubicin
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Baylor College of Medicine
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia
This is a phase I, dose-escalation, open-label clinical trial determining the safety and tolerability of adding Pitavastatin to Venetoclax in subjects with chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML).
- Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, AML, Adult, CLL
- Trial name
- NCT04512105
- Testing
- Pitavastatin, Venetoclax
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Irvine
Lymphoproliferative Malignancies, Acute Myeloid Leukemia
Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
The purpose of this study is to determine safety, tolerability, dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of ZEN003365 in patients with relapsed/refractory lymphoproliferative malignancies (LPM) or…
- Trial name
- NCT02238522
- Testing
- ZEN003365
- Where
- 4 sites in United States
- Sponsor
- Zenith Epigenetics
Acute Myeloid Leukemia NOS
Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia
Primary Objective: Measure the proportion of patients who develop binding and neutralizing antibodies in the blood after treatment with sargramostim following induction/reinduction chemotherapy.
- Trial name
- NCT02520102
- Testing
- sargramostim GZ402664
- Sponsor
- Sanofi
Core Binding Factor Acute Myeloid Leukemia (CBF-AML)
Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia
The purpose of this single-arm, open label, phase-II trial, is to determine whether the association of Midostaurin to standard induction, consolidation therapy and in maintenance therapy as single agent, is effective in decrease…
- Trial name
- AML FLT3 (NCT03686345)
- Testing
- Midostaurin
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- Niguarda Hospital
Acute Myeloid Leukemia, AML
Study of XL999 in Patients With Acute Myeloid Leukemia (AML)
This clinical study is being conducted at multiple sites to determine the activity, safety and tolerability of XL999 when given weekly to patients with relapsed or newly-diagnosed AML.
- Trial name
- NCT00322673
- Testing
- XL999
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Symphony Evolution, Inc.
Leukemia, Myelocytic, Acute
Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)
The AML-03 regimen investigates the addition of G-CSF priming to both induction and consolidation chemotherapies administrated in the previous AML-99 trial (NCT01716793) refines risk-stratification based on biological…
- Trial name
- NCT01723657
- Testing
- Ara-C, Autologous peripheral blood stem cell transplantation., Allogeneic matched related or unrelated donor transplant.
- Where
- 21 sites in Spain
- Volunteers
- 862 people
- Sponsor
- Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS
This is a two strata Phase 1b study to assess the safety and efficacy of bisantrene (RC110) in combination with a) cytarabine arabinoside (Ara-C) treatment for patients with relapsed or refractory (R/R) Acute Myeloid Leukemia…
- Conditions
- Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Higher Risk Myelodysplastic Syndrome
- Trial name
- BISECT (NCT05456269)
- Testing
- Bisantrene Dihydrochloride (high dose), Bisantrene Dihydrochloride (low dose), Cytarabine Hydrochloride
- Where
- Australia
- Sponsor
- Racura Oncology Ltd
Malignancy, Hematologic, Neoplasms, Hematologic
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes.
- Conditions
- Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer
- Trial name
- NCT06904066
- Testing
- aldesleukin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS
The goal of this clinical research study is to find the highest safe dose of Mylotarg that can be combined with chemotherapy in patients receiving allogeneic bone marrow transplantation.
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia
- Trial name
- NCT00038831
- Testing
- Mylotarg, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myeloid
High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML
The purpose of this study is to evaluate the safety and efficiency of high dose allogeneic mismatched hematopoietic stem cells infusions after normal chemotherapy in patients with relapsed/refractory acute myeloid leukemia（AML）.
- Trial name
- NCT03080922
- Testing
- hematopoietic stem cell
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Leukemia, Myeloid, Acute
Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML
This is a pilot efficacy assessment clinical trial of vosaroxin and cytarabine for the treatment of adults 60 years of age or older with previously untreated acute myeloid leukemia.
- Trial name
- NCT02485353
- Testing
- Vosaroxin and Cytarabine
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Hamid Sayar
Leukemia
Drug Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying cell samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer PURPOSE: This research study is studying drug…
- Trial name
- NCT01150058
- Testing
- western blotting, flow cytometry, laboratory biomarker analysis
- Volunteers
- 40 people
- Sponsor
- Children's Oncology Group
Chronic Myeloproliferative Disorders, Leukemia
Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00066417
- Testing
- cyclophosphamide, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
AML - Acute Myeloid Leukemia, AML With Mutated NPM1
Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
The goal of this clinical trial is to test BSB-2002 which is a new type of cellular therapy to treat blood cancer (AML). It will evaluate the safety of BSB-2002 and also determine whether it works to prevent relapse of your…
- Conditions
- AML - Acute Myeloid Leukemia, AML With Mutated NPM1, AML, Adult Recurrent
- Trial name
- NCT07566585
- Testing
- SOC+ BSB-2002, SOC+BSB-2002
- Where
- United States
- Sponsor
- BlueSphere Bio, Inc
Acute Myeloblastic Leukaemia, Leukemia, T-Cell
Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
This Phase I/IIa clinical study is testing an experimental treatment called GYA01 (CART84) for people with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) whose disease has come back after treatment…
- Trial name
- NCT07471789
- Testing
- CART84
- Where
- 2 sites in Spain
- Volunteers
- 33 people
- Sponsor
- Gyala Therapeutics
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results
Genetic mutations have closely linked to the pathogenesis and prognostication of myeloid cancers. In addition, a number of molecularly targeted agents have been developed in recent years.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Aplastic Anemia
- Trial name
- NCT04060485
- Where
- Taiwan
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Leukemia
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of lenalidomide that can be given in combination with azacitidine to patients with MDS or AML.
- Trial name
- NCT01038635
- Testing
- 5-Azacytidine, Lenalidomide
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
Study of Dosage Individualisation for the Treatment of Acute Myeloid Leukemia
The present study is not hypothesis driven but will explore the ability of pharmacokinetic-pharmacodynamic modelling to predict optimal dosage of the chemotherapeutic drugs used in therapy in adult patients with acute myeloid…
- Trial name
- NCT00969891
- Testing
- PK-PD analysis
- Where
- 2 sites in Denmark
- Volunteers
- 23 people
- Sponsor
- Mikkel Krogh-Madsen
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
This is an open label, interventional, randomized phase II trial comparing StemRegenin-1 (SR-1) cultured umbilical cord blood (experimental arm) to unmanipulated umbilical cord blood (standard of care arm) transplantation after a…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia
- Trial name
- NCT02765997
- Testing
- Unmanipulated UCB, SR-1 UCB
- Where
- United States
- Sponsor
- Masonic Cancer Center, University of Minnesota
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.